Hepatitis Monthly
Official Journal of Research Center for Gastroenterology and Liver Diseases
Scopus by Title (Ref)
3. Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma
- Huq S. , et al.
4. Critical view on the usage of ribavirin in already existing psychostimulant-use disorder
- Petković B. , et al.
5. Psychomotor activity and body weight gain after exposure to low ribavirin doses in rats: Role of treatment duration
- Petković B. , et al.
6. Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferonalpha and ribavirin - A prospective study
- Ružić M. , et al.
7. Changes in hematological parameters with pegylated interferon in chronic hepatitis C virus infected patients
- Rehman A.U. , et al.
8. Vitamin D and chronic hepatitis C: Effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin
- Refaat B. , et al.
9. Activins and follistatin in chronic hepatitis c and its treatment with pegylated-interferon-α based therapy
- Refaat B. , et al.
10. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3
- Abenavoli L. , et al.
11. Mysterious linkages between hepatitis C virus genotypes, interleukin-28B genotypes and viral clearance- a meta-analysis
- Aalaei-Andabili S.H. , et al.
12. Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C
- Brochot E. , et al.
13. Silymarin flavonolignans: Structure-activity relationship and biosynthesis
- Abouzid S. , et al.
14. Commentary on: The Optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical Practice
- El-Shabrawi M. , et al.
15. Induction with ribavirin in a relapsing patient with chronic HCV hepatitis
- Ucciferri C. , et al.